FoxO1 Is Required for Most of the Metabolic and Hormonal Perturbations Produced by Hepatic Insulin Receptor Deletion in Male Mice

Endocrinology

Volumn 159, Issue 3, 2018, Pages 1253-1263

  Ling, Alisha V ^a   Gearing, Mary E ^a   Semova, Ivana ^a   Shin, Dong Ju ^a   Clements, Rebecca ^a   Lai, Zon W ^b   Biddinger, Sudha B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CHOLINE ETHANOLAMINE PHOSPHOTRANSFERASE 1; CHOLINE KINASE; CRE RECOMBINASE; DIACYLGLYCEROL; GLUCOSE; GLUCOSE 6 PHOSPHATASE; INSULIN; INSULIN RECEPTOR; LEPTIN; LEPTIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; FATTY ACID; LIPID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE DELETION; GENE EXPRESSION; GLUCOSE LEVEL; GLUCOSE TOLERANCE; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID LIVER LEVEL; LIPOGENESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSGENE; ANALYSIS; ANIMAL; BLOOD; C57BL MOUSE; CHEMISTRY; DEFICIENCY; GENETICS; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; KNOCKOUT MOUSE; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; FATTY ACIDS; FORKHEAD BOX PROTEIN O1; GENE EXPRESSION; GLUCONEOGENESIS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; LIPIDS; LIPOGENESIS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXIDATION-REDUCTION; RECEPTOR, INSULIN; RECEPTORS, LEPTIN; TRIGLYCERIDES;

EID: 85042639298     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2017-00870     Document Type: Article

References (54)

1. Biddinger SB, Kahn CR. From mice to men: insights into the insulin resistance syndromes. Annu Rev Physiol. 2006;68(1):123-158.
2. Michael MD, Kulkarni RN, Postic C, Previs SF, Shulman GI, Magnuson MA, Kahn CR. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87-97.
3. Biddinger SB, Hernandez-OnoA,Rask-Madsen C,Haas JT, Alemán JO, Suzuki R, Scapa EF, Agarwal C, CareyMC, Stephanopoulos G, Cohen DE, King GL, Ginsberg HN, Kahn CR. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008;7(2):125-134.
4. Haas JT, Miao J, Chanda D, Wang Y, Zhao E, Haas ME, Hirschey M, Vaitheesvaran B, Farese RV, Jr, Kurland IJ, Graham M, Crooke R, Foufelle F, Biddinger SB. Hepatic insulin signaling is required for obesity-dependent expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab. 2012;15(6): 873-884.
5. Titchenell PM, Chu Q, Monks BR, Birnbaum MJ. Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat Commun. 2015;6:7078.
6. O-Sullivan I, Zhang W, Wasserman DH, Liew CW, Liu J, Paik J, DePinho RA, Stolz DB, Kahn CR, Schwartz MW, Unterman TG. FoxO1 integrates direct and indirect effects of insulin on hepatic glucose production and glucose utilization. Nat Commun. 2015;6: 7079.
7. Cohen SE, Kokkotou E, Biddinger SB, Kondo T, Gebhardt R, Kratzsch J, Mantzoros CS, Kahn CR. High circulating leptin receptors with normal leptin sensitivity in liver-specific insulin receptor knock-out (LIRKO) mice. J Biol Chem. 2007; 282(32): 23672-23678
8. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA, White MF. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell Metab. 2008;8(1):65-76.
9. Lu M, Wan M, Leavens KF, Chu Q, Monks BR, Fernandez S, Ahima RS, Ueki K, Kahn CR, Birnbaum MJ. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18(3):388-395.
10. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, Bhanot S, McKay R, Monia B, Shutter JR, Lindberg RA, Shulman GI, Veniant MM. Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes. 2006;55(7):2042-2050.
11. Wan M, Leavens KF, Saleh D, Easton RM, Guertin DA, Peterson TR, Kaestner KH, Sabatini DM, Birnbaum MJ. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 2011;14(4):516-527.
12. Haeusler RA, Kaestner KH, Accili D. FoxOs function synergistically to promote glucose production. J Biol Chem. 2010;285(46): 35245-35248.
13. Haeusler RA, Pratt-Hyatt M, Welch CL, Klaassen CD, Accili D. Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia. Cell Metab. 2012;15(1):65-74.
14. Zhang K, Li L, Qi Y, Zhu X, Gan B, DePinho RA, Averitt T, Guo S. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology. 2012;153(2):631-646.
15. Paik JH, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA. FoxOs are lineagerestricted redundant tumor suppressors and regulate endothelial cell homeostasis. Cell. 2007;128(2):309-323.
16. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917.
17. Zastrow O, Seidel B, Kiess W, Thiery J, Keller E, Böttner A, Kratzsch J. The soluble leptin receptor is crucial for leptin action: evidence from clinical and experimental data. Int J Obes Relat Metab Disord. 2003;27(12):1472-1478.
18. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriarty A, Moore KJ, Smutko JS, Mays GG, Wool EA, Monroe CA, Tepper RI. Identification and expression cloning of a leptin receptor, OB-R. Cell. 1995;83(7):1263-1271.
19. Huang L, Wang Z, Li C. Modulation of circulating leptin levels by its soluble receptor. J Biol Chem. 2001;276(9):6343-6349.
20. Maamra M, Bidlingmaier M, Postel-Vinay MC,Wu Z, Strasburger CJ, Ross RJ. Generation of human soluble leptin receptor by proteolytic cleavage of membrane-anchored receptors. Endocrinology. 2001;142(10):4389-4393.
21. Yabe D, Brown MS, Goldstein JL. Insig-2, a second endoplasmic reticulum protein that binds SCAP and blocks export of sterol regulatory element-binding proteins. Proc Natl Acad Sci USA. 2002;99(20):12753-12758.
22. Yabe D, Komuro R, Liang G, Goldstein JL, Brown MS. Liverspecific mRNA for Insig-2 down-regulated by insulin: implications for fatty acid synthesis. Proc Natl Acad Sci USA. 2003;100(6): 3155-3160.
23. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR, Gout I, Downes CP, Lamb RF. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166(2):213-223.
24. Halldin MU, Hagenäs L, Tuvemo T, Gustafsson J. Profound changes in the GH-IGF-I system in adolescent girls with IDDM: can IGFBP1 be used to reflect overall glucose regulation Pediatr Diabetes. 2000;1(3):121-130.
25. Massa G, Dooms L, Bouillon R, Vanderschueren-Lodeweyckx M. Serum levels of growth hormone-binding protein and insulin-like growth factor I in children and adolescents with type 1 (insulindependent) diabetes mellitus. Diabetologia. 1993;36(3):239-243.
26. Raisingani M, Preneet B, Kohn B, Yakar S. Skeletal growth and bone mineral acquisition in type 1 diabetic children; abnormalities of the GH/IGF-1 axis. Growth Horm IGF Res. 2017;34:13-21.
27. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96(13):7324-7329.
28. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, Mombaerts P, Friedman JM. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest. 2001;108(8):1113-1121.
29. Lou PH, Yang G, Huang L, Cui Y, Pourbahrami T, Radda GK, Li C, Han W. Reduced body weight and increased energy expenditure in transgenic mice over-expressing soluble leptin receptor. PLoS One. 2010;5(7):e11669.
30. Tu H, Kastin AJ, Hsuchou H, Pan W. Soluble receptor inhibits leptin transport. J Cell Physiol. 2008;214(2):301-305.
31. Yang G, Ge H, Boucher A, Yu X, Li C. Modulation of direct leptin signaling by soluble leptin receptor. Mol Endocrinol. 2004;18(6): 1354-1362.
32. Petersen MC, Shulman GI. Roles of diacylglycerols and ceramides in hepatic insulin resistance. Trends Pharmacol Sci. 2017;38(7): 649-665.
33. Luukkonen PK, Zhou Y, Sädevirta S, Leivonen M, Arola J, Oresic M, Hyötyläinen T, Yki-Järvinen H. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J Hepatol. 2016;64(5):1167-1175.
34. Magkos F, Su X, Bradley D, Fabbrini E, Conte C, Eagon JC, Varela JE, Brunt EM, Patterson BW, Klein S. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology. 2012;142(7):1444-1446.e2.
35. Turpin SM, Nicholls HT, Willmes DM, Mourier A, Brodesser S, Wunderlich CM,Mauer J, Xu E,Hammerschmidt P, BrönnekeHS, Trifunovic A, LoSasso G,Wunderlich FT, Kornfeld JW, BlüherM, Krönke M, Brüning JC. Obesity-induced CerS6-dependent C16: 0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014;20(4):678-686.
36. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, Chu X, Still CD, Gerhard GS, Han X, Dziura J, Petersen KF, Samuel VT, Shulman GI. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. Proc Natl Acad Sci USA. 2011; 108(39):16381-16385.
37. Wendel AA, Cooper DE, Ilkayeva OR, Muoio DM, Coleman RA. Glycerol-3-phosphate acyltransferase (GPAT)-1, but not GPAT4, incorporates newly synthesized fatty acids into triacylglycerol and diminishes fatty acid oxidation. J Biol Chem. 2013;288(38): 27299-27306.
38. Wendel AA, Lewin TM, Coleman RA. Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim Biophys Acta. 2009;1791(6):501-506.
39. Haeusler RA, Han S, Accili D. Hepatic FoxO1 ablation exacerbates lipid abnormalities during hyperglycemia. J Biol Chem. 2010; 285(35):26861-26868.
40. Inagaki T,Dutchak P, Zhao G, DingX, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007;5(6):415-425.
41. HottaY,NakamuraH,Konishi M,Murata Y, TakagiH,Matsumura S, Inoue K, Fushiki T, Itoh N. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 2009;150(10): 4625-4633.
42. Li X, Ge H, Weiszmann J, Hecht R, Li YS, Véniant MM, Xu J, Wu X, Lindberg R, Li Y. Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett. 2009;583(19):3230-3234.
43. Yang C, Wang C, Ye M, Jin C, He W, Wang F, McKeehan WL, Luo Y. Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress. Nutr Metab (Lond). 2012;9(1):94.
44. Perry RJ, Camporez JP, Kursawe R, Titchenell PM, Zhang D, Perry CJ, Jurczak MJ, Abudukadier A, Han MS, Zhang XM, Ruan HB, Yang X, Caprio S, Kaech SM, Sul HS, Birnbaum MJ, Davis RJ, Cline GW, Petersen KF, Shulman GI. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell. 2015;160(4):745-758.
45. Bolinder J, Lindblad A, Engfeldt P, Arner P. Studies of acute effects of insulin-like growth factors I and II in human fat cells. J Clin Endocrinol Metab. 1987;65(4):732-737.
46. Siegrist-Kaiser CA, Pauli V, Juge-Aubry CE, Boss O, Pernin A, Chin WW, Cusin I, Rohner-Jeanrenaud F, Burger AG, Zapf J, Meier CA. Direct effects of leptin on brown and white adipose tissue. J Clin Invest. 1997;100(11):2858-2864.
47. Horton JD. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem Soc Trans. 2002;30(6): 1091-1095.
48. Attie AD. Insig: a significant integrator of nutrient and hormonal signals. J Clin Invest. 2004;113(8):1112-1114.
49. Miao J, Haas JT, Manthena P, Wang Y, Zhao E, Vaitheesvaran B, Kurland IJ, Biddinger SB. Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins. J Lipid Res. 2014;55(4):659-667.
50. Titchenell PM, Quinn WJ, Lu M, Chu Q, Lu W, Li C, Chen H, Monks BR, Chen J, Rabinowitz JD, Birnbaum MJ. Direct hepatocyte insulin signaling is required for lipogenesis but is dispensable for the suppression of glucose production. Cell Metab. 2016;23(6): 1154-1166.
51. Haeusler RA, Hartil K, Vaitheesvaran B, Arrieta-Cruz I, Knight CM, Cook JR, Kammoun HL, Febbraio MA, Gutierrez-Juarez R, Kurland IJ, Accili D. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun. 2014;5:5190.
52. Langlet F, Haeusler RA, Linden D, Ericson E, Norris T, Johansson A, Cook JR, Aizawa K, Wang L, Buettner C, Accili D. Selective inhibition of FOXO1 activator/repressor balance modulates hepatic glucose handling. Cell. 2017;171(4):824-835.e18.
53. Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA. 1998;95(11):5987-5992.
54. Dentin R, Pégorier JP, Benhamed F, Foufelle F, Ferré P, Fauveau V, Magnuson MA, Girard J, Postic C. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem. 2004; 279(19):20314-20326.